IS5568A - Lyfjafræðilega virkt morfólínól - Google Patents

Lyfjafræðilega virkt morfólínól

Info

Publication number: IS5568A
Authority: IS; Iceland
Prior art keywords: pharmacologically active; morpholinol; active morpholinol; pharmacologically; active
Prior art date: 1998-01-21

Application number

IS5568A

Other languages

English (en)

Other versions

IS2494B (is

Inventor

Frederick Morgan Phillip

Lee Musso David

Joseph Partridge John

Original Assignee

Glaxo Group Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-21

Filing date

2000-07-20

Publication date

2000-07-20

1998-01-21 Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en

2000-07-20 Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited

2000-07-20 Publication of IS5568A publication Critical patent/IS5568A/is

2009-02-15 Publication of IS2494B publication Critical patent/IS2494B/is

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Diabetes (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IS5568A 1998-01-21 2000-07-20 Notkun á morfólínóli til meðhöndlunar á kynferðislegri vanvirkni IS2494B (is)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9801230.5A GB9801230D0 (en)	1998-01-21	1998-01-21	Pharmaceutically active morpholinol
US7218098P	1998-01-22	1998-01-22
PCT/US1999/001134 WO1999037305A1 (en)	1998-01-21	1999-01-20	Pharmaceutically active morpholinol

Publications (2)

Publication Number	Publication Date
IS5568A true IS5568A (is)	2000-07-20
IS2494B IS2494B (is)	2009-02-15

Family

ID=26312986

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS5568A IS2494B (is)	1998-01-21	2000-07-20	Notkun á morfólínóli til meðhöndlunar á kynferðislegri vanvirkni

Country Status (30)

Country	Link
US (2)	US6274579B1 (is)
EP (2)	EP1047428B1 (is)
JP (1)	JP2002501025A (is)
KR (1)	KR100568063B1 (is)
CN (2)	CN1203858C (is)
AP (1)	AP1229A (is)
AT (1)	ATE365042T1 (is)
AU (1)	AU755536B2 (is)
BR (1)	BR9907203A (is)
CA (1)	CA2318268A1 (is)
CY (1)	CY1106828T1 (is)
DE (1)	DE69936335T2 (is)
DK (1)	DK1047428T3 (is)
EA (1)	EA002410B1 (is)
EE (1)	EE04452B1 (is)
ES (1)	ES2288012T3 (is)
HR (2)	HRP20051024A2 (is)
HU (1)	HUP0100900A3 (is)
ID (1)	ID26334A (is)
IL (2)	IL137346A0 (is)
IS (1)	IS2494B (is)
NO (2)	NO326878B1 (is)
NZ (3)	NZ505809A (is)
PL (1)	PL193622B1 (is)
PT (1)	PT1047428E (is)
SG (1)	SG115489A1 (is)
SK (1)	SK10912000A3 (is)
TR (1)	TR200002126T2 (is)
WO (1)	WO1999037305A1 (is)
YU (1)	YU67102A (is)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7098206B2 (en) *	1998-01-21	2006-08-29	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6998400B2 (en)	1998-01-22	2006-02-14	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
JP2002501892A (ja)	1998-01-29	2002-01-22	セプラコアインコーポレーテッド	光学的に純粋な（−）−ビュープロピオンの薬学的使用
CA2318921A1 (en) *	1998-01-29	1999-08-05	John R. Mccullough	Pharmacological uses of optically pure (+)-bupropion
US6855820B2 (en)	1999-01-20	2005-02-15	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6734213B2 (en)	1999-01-20	2004-05-11	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6337328B1 (en) *	1999-03-01	2002-01-08	Sepracor, Inc.	Bupropion metabolites and methods of use
US6342496B1 (en) *	1999-03-01	2002-01-29	Sepracor Inc.	Bupropion metabolites and methods of use
AU7750100A (en) *	1999-10-13	2001-04-23	Glaxo Group Limited	Method for the treatment of obesity
GB0003232D0 (en) *	2000-02-11	2000-04-05	Smithkline Beecham Plc	Novel composition
CA2365428C (en) *	2000-12-21	2008-10-21	Brasscorp Limited	Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing
US6979104B2 (en)	2001-12-31	2005-12-27	R.J. Doran & Co. LTD	LED inspection lamp
US20050215552A1 (en) *	2002-05-17	2005-09-29	Gadde Kishore M	Method for treating obesity
EP2301537A1 (en) *	2002-05-17	2011-03-30	Duke University	Zonisamide for the treatment of obesity
ATE413882T1 (de) *	2002-08-23	2008-11-15	Lilly Co Eli	2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin- wiederaufnahme-inhibitoren
GB0219687D0 (en) *	2002-08-23	2002-10-02	Lilly Co Eli	Benzyl morpholine derivatives
KR101167579B1 (ko)	2003-04-29	2012-07-27	오렉시젠 세러퓨틱스 인크.	체중감량용 조성물
US20070093486A1 (en) *	2003-10-27	2007-04-26	Smith Kline Beecham Corporation ,Corporation	Enzyme-catalyzed dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinoland salts and solvates thereof
GB0325055D0 (en) *	2003-10-27	2003-12-03	Smithkline Beecham Corp	New process
GB0326148D0 (en)	2003-11-10	2003-12-17	Lilly Co Eli	Morpholine derivatives
GB0327195D0 (en) *	2003-11-21	2003-12-24	Smithkline Beecham Corp	Novel use
GB0327619D0 (en) *	2003-11-27	2003-12-31	Smithkline Beecham Corp	New use
US7429580B2 (en) *	2004-01-13	2008-09-30	Orexigen Therapeutics, Inc.	Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US7713959B2 (en) *	2004-01-13	2010-05-11	Duke University	Compositions of an anticonvulsant and mirtazapine to prevent weight gain
CA2565154A1 (en) *	2004-05-03	2005-11-24	Duke University	Compositions for affecting weight loss
FI117283B (fi)	2005-02-04	2006-08-31	Kone Corp	Hissijärjestelmä
PT2135603E (pt)	2005-11-22	2013-04-03	Orexigen Therapeutics Inc	Composições e métodos para aumentar a sensibilidade à insulina
WO2007079470A2 (en)	2006-01-03	2007-07-12	Algebra, Inc.	Therapeutic amine-arylsulfonamide conjugate compounds
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
TW200829235A (en)	2006-11-09	2008-07-16	Orexigen Therapeutics Inc	Methods for administering weight loss medications
JP2010509367A (ja)	2006-11-09	2010-03-25	オレキシジェン・セラピューティクス・インコーポレーテッド	積層製剤
US20090075994A1 (en) *	2007-09-14	2009-03-19	Protia, Llc	Deuterium-enriched radafaxine
EP2303025A4 (en)	2008-05-30	2012-07-04	Orexigen Therapeutics Inc	METHOD FOR TREATING DIGITAL FAT SWITCHES
AU2010236404B2 (en)	2009-04-15	2016-11-03	Research Triangle Institute	Monoamine reuptake inhibitors
EP2523557B1 (en)	2010-01-11	2019-09-25	Nalpropion Pharmaceuticals, Inc.	Methods of providing weight loss therapy in patients with major depression
WO2011146850A1 (en)	2010-05-21	2011-11-24	Research Triangle Institute	Phenylmorpholines and analogues thereof
EP2571859B1 (en) *	2010-05-21	2015-07-22	Research Triangle Institute	1-phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence
US9510405B2 (en)	2011-06-30	2016-11-29	Schneider Electric Industries Sas	Dual power SMPS for a modular lighting system
CN102670617B (zh) *	2012-04-13	2013-03-20	湖南大学	布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
KR20230010811A (ko)	2012-06-06	2023-01-19	오렉시젠 세러퓨틱스 인크.	과체중 및 비만의 치료 방법
CN105949142B (zh) *	2016-05-21	2018-03-27	南华大学	具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) *	2021-06-17	2021-12-30	Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ)	Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US170430A (en) *		1875-11-30		Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) *	1984-07-05	1984-08-08	Wellcome Found	Heterocyclic pharmaceutical compounds
GB9108629D0 (en)	1991-04-23	1991-06-12	Wellcome Found	Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en)	1999-03-01	2002-01-08	Sepracor, Inc.	Bupropion metabolites and methods of use

1999
- 1999-01-20 HR HR20051024A patent/HRP20051024A2/hr not_active Application Discontinuation
- 1999-01-20 SG SG200204411A patent/SG115489A1/en unknown
- 1999-01-20 AT AT99903200T patent/ATE365042T1/de active
- 1999-01-20 EP EP99903200A patent/EP1047428B1/en not_active Expired - Lifetime
- 1999-01-20 IL IL13734699A patent/IL137346A0/xx not_active IP Right Cessation
- 1999-01-20 CN CNB998042706A patent/CN1203858C/zh not_active Expired - Fee Related
- 1999-01-20 BR BR9907203-3A patent/BR9907203A/pt not_active Application Discontinuation
- 1999-01-20 ID IDW20001597A patent/ID26334A/id unknown
- 1999-01-20 CN CNB2004100085595A patent/CN1255389C/zh not_active Expired - Fee Related
- 1999-01-20 EA EA200000691A patent/EA002410B1/ru not_active IP Right Cessation
- 1999-01-20 AP APAP/P/2000/001869A patent/AP1229A/en active
- 1999-01-20 WO PCT/US1999/001134 patent/WO1999037305A1/en not_active Ceased
- 1999-01-20 HR HR20000494A patent/HRP20000494B1/xx not_active IP Right Cessation
- 1999-01-20 JP JP2000528287A patent/JP2002501025A/ja active Pending
- 1999-01-20 SK SK1091-2000A patent/SK10912000A3/sk unknown
- 1999-01-20 KR KR1020007007996A patent/KR100568063B1/ko not_active Expired - Fee Related
- 1999-01-20 TR TR2000/02126T patent/TR200002126T2/xx unknown
- 1999-01-20 NZ NZ505809A patent/NZ505809A/xx unknown
- 1999-01-20 EP EP07110283A patent/EP1829544A1/en not_active Withdrawn
- 1999-01-20 DE DE69936335T patent/DE69936335T2/de not_active Expired - Lifetime
- 1999-01-20 NZ NZ529316A patent/NZ529316A/en unknown
- 1999-01-20 CA CA002318268A patent/CA2318268A1/en not_active Abandoned
- 1999-01-20 DK DK99903200T patent/DK1047428T3/da active
- 1999-01-20 US US09/233,531 patent/US6274579B1/en not_active Expired - Fee Related
- 1999-01-20 NZ NZ520349A patent/NZ520349A/en unknown
- 1999-01-20 PL PL99342012A patent/PL193622B1/pl not_active IP Right Cessation
- 1999-01-20 AU AU23280/99A patent/AU755536B2/en not_active Ceased
- 1999-01-20 EE EEP200000438A patent/EE04452B1/xx not_active IP Right Cessation
- 1999-01-20 ES ES99903200T patent/ES2288012T3/es not_active Expired - Lifetime
- 1999-01-20 IL IL16194299A patent/IL161942A0/xx unknown
- 1999-01-20 HU HU0100900A patent/HUP0100900A3/hu unknown
- 1999-01-20 PT PT99903200T patent/PT1047428E/pt unknown
2000
- 2000-07-20 IS IS5568A patent/IS2494B/is unknown
- 2000-07-20 NO NO20003721A patent/NO326878B1/no not_active IP Right Cessation
2001
- 2001-06-22 US US09/886,391 patent/US6391875B2/en not_active Expired - Fee Related
2002
- 2002-09-06 YU YU67102A patent/YU67102A/sh unknown
2007
- 2007-08-31 CY CY20071101117T patent/CY1106828T1/el unknown
2008
- 2008-08-14 NO NO20083529A patent/NO20083529L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
HUP0100900A3 (en)	2002-08-28
EE04452B1 (et)	2005-04-15
AU755536B2 (en)	2002-12-12
US20020019396A1 (en)	2002-02-14
HRP20000494B1 (en)	2009-02-28
NO20083529L (no)	2000-09-19
HRP20051024A2 (hr)	2006-04-30
WO1999037305A1 (en)	1999-07-29
NZ505809A (en)	2002-09-27
NZ529316A (en)	2004-05-28
YU67102A (sh)	2004-12-31
AU2328099A (en)	1999-08-09
PT1047428E (pt)	2007-09-07
PL193622B1 (pl)	2007-02-28
DE69936335T2 (de)	2008-02-28
EP1047428B1 (en)	2007-06-20
CN1528753A (zh)	2004-09-15
KR20010034285A (ko)	2001-04-25
JP2002501025A (ja)	2002-01-15
SK10912000A3 (sk)	2001-04-09
IL137346A0 (en)	2001-07-24
SG115489A1 (en)	2005-10-28
EP1829544A1 (en)	2007-09-05
NO20003721L (no)	2000-09-19
US6274579B1 (en)	2001-08-14
CN1255389C (zh)	2006-05-10
EP1047428A4 (en)	2001-12-19
AP1229A (en)	2003-12-04
DK1047428T3 (da)	2007-10-08
BR9907203A (pt)	2000-10-17
CY1106828T1 (el)	2012-05-23
CN1203858C (zh)	2005-06-01
NO326878B1 (no)	2009-03-09
EP1047428A1 (en)	2000-11-02
IL161942A0 (en)	2005-11-20
EE200000438A (et)	2001-12-17
US6391875B2 (en)	2002-05-21
KR100568063B1 (ko)	2006-04-07
CN1294513A (zh)	2001-05-09
AP2000001869A0 (en)	2000-09-30
ID26334A (id)	2000-12-14
NO20003721D0 (no)	2000-07-20
PL342012A1 (en)	2001-05-07
DE69936335D1 (de)	2007-08-02
ES2288012T3 (es)	2007-12-16
ATE365042T1 (de)	2007-07-15
EA200000691A1 (ru)	2001-04-23
EA002410B1 (ru)	2002-04-25
NZ520349A (en)	2004-02-27
TR200002126T2 (tr)	2000-12-21
HUP0100900A2 (hu)	2002-05-29
CA2318268A1 (en)	1999-07-29
IS2494B (is)	2009-02-15
HRP20000494A2 (en)	2000-12-31

Publication	Publication Date	Title
IS5568A (is)	2000-07-20	Lyfjafræðilega virkt morfólínól
PT1220856E (pt)	2005-02-28	Compostos farmaceuticamente activos
MA26473A1 (fr)	2004-12-20	Composes pharmacologiquement actifs.
DE60044873D1 (de)	2010-10-07	Orientierte biopolymermembrane
DE60009395D1 (de)	2004-05-06	Bildanzeige
ATA51899A (de)	2002-04-15	Handstempel
ATE357433T1 (de)	2007-04-15	4-pyrimidinyl-n-acyl-l-phenylanine
ES1047774Y (es)	2001-10-01	Estructura de electrodo
NO993443D0 (no)	1999-07-13	Kabinstruktur
ATE297895T1 (de)	2005-07-15	4-pyridinyl-n-acyl-l-phenylalanine
DE59912684D1 (de)	2006-03-02	Folienförmige wirkstoffträger
DE60011330D1 (de)	2004-07-15	Elektrode
EP1005862A4 (en)	2001-05-16	ANTI-CHLAMYDIA MEDIUM
DE50015795D1 (de)	2009-12-24	Sektionaltor
DE59902159D1 (de)	2002-08-29	Aktiver mikromischer
NO20005769L (no)	2000-11-14	Cyklosporinderivater
NO20005325L (no)	2000-10-24	Bjelkelagskonstruksjon
ATE269311T1 (de)	2004-07-15	Benzoylpyridazine
ATA121799A (de)	2002-03-15	Ausbeulgerät
DE69901485D1 (de)	2002-06-20	Doppelfunktions-strukturen
IS8740A (is)	2008-06-27	Lyfjafræðilega virkt morfólínól
ATA107599A (de)	2002-06-15	Heizwasserbereiter
DE60004561D1 (de)	2003-09-18	Aktive baugruppe
SE9802539D0 (sv)	1998-07-13	New pharmaceutically active compounds
AT500658A3 (de)	2007-10-15	Isolierplatte